STAT

Opinion: Peer review could help smoke out the next Theranos

The insidious problem with health care unicorns is not one-off, ripe-for-cinema scandal — think Theranos. It is the absence of credible scientific evidence.
Source: APStock

Over a 25-month period, the startup Theranos plummeted from the heights of biotech, with a valuation of $9 billion and a fawning profile in the New Yorker’s “Annals of Innovation” in December 2014, to thanatos (death) when the company shuttered its final laboratory in January 2017. By early 2018, joint investigations by the Securities and Exchange Commission and the Food and Drug Administration, impending bankruptcy, mass layoffs, and fraud charges against the company’s enigmatic founder, Elizabeth Holmes, finished off the so-called unicorn.

Not long after the sentinel New Yorker profile appeared, one of us (J.P.A.I.) about Theranos’ operation in a JAMA Viewpoint. One major concern was that the company hadn’t presented a shred of

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
It’s Not Just Bosses Who Harass Health Workers: Hospitals Start Addressing Patients’ ‘Egregious’ Behavior
There's growing awareness that it’s not just bosses and colleagues who sexually harass health care workers. Often, it’s the patients who are doing the harassing.
STAT5 min readSociety
Opinion: Wider Use Of Assisted Outpatient Treatment Could Help Individuals With Mental Illness
Many states still rely on laws that require individuals to become dangerous to themselves or others before they can be treated without their consent. We need laws that that prevent…
STAT9 min readSociety
‘The Switch’ Was Supposed To Be A Major Step Toward Eradicating Polio. Now It’s A Quandary
A change in polio vaccination policies was supposed to put the world on a better footing to finally eliminate a global scourge. It's gotten complicated.